No Data
No Data
Earnings Call: 23andMe Reports Decreased Revenue, Narrows Losses
Earnings Call Summary | 23andMe(ME.US) Q1 2025 Earnings Conference
23andMe Shuts Down Therapeutics Discovery Unit, Launching GLP-1 Telehealth Offering
23andMe Holding Co. (ME) Q1 2025 Earnings Call Transcript
Former Wall Street darling 23andMe is in trouble and is entering the weight loss drug market with all its might.
According to a press release published on Thursday, the company plans to launch a weight-loss membership program on its telemedicine platform Lemonaid by the end of this month. Users will be able to obtain brand-name drugs or combination preparations of semaglutide, the active ingredient in the Novo Nordisk blockbuster weight-loss drug, on the platform. 23andMe also plans to launch a new genetic study focusing on popular diabetes and weight-loss drugs to identify gene variants associated with weight loss and side effects.
Express News | 23Andme Holding Co. Qtrly Shr Loss $0.14
No Data